Back to Journals » Therapeutics and Clinical Risk Management » Volume 8 » default

Therapeutics and Clinical Risk Management


Archive: Volume 8, 2012

Appropriateness of administration of nasogastric medication and preliminary intervention

Zhu LL, Xu LC, Wang HQ, Jin JF, Wang HF, Zhou Q

Therapeutics and Clinical Risk Management 2012, 8:393-401

Published Date: 20 November 2012

Consequences of neurologic lesions assessed by Barthel Index after Botox® injection may be underestimated

Dionyssiotis Y, Kiourtidis D, Karvouni A, Kaliontzoglou A, Kliafas I

Therapeutics and Clinical Risk Management 2012, 8:385-391

Published Date: 19 October 2012

Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy

Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL

Therapeutics and Clinical Risk Management 2012, 8:377-384

Published Date: 17 September 2012

Extreme intrafamilial variability of Saudi brothers with primary hyperoxaluria type 1

Alfadhel M, Alhasan KA, Alotaibi M, Al Fakeeh K

Therapeutics and Clinical Risk Management 2012, 8:373-376

Published Date: 28 August 2012

Efficacy of serum chitotriosidase activity in early treatment of patients with active tuberculosis and a negative sputum smear

Tasci C, Tapan S, Ozkaya S, Demirer E, Deniz O, Balkan A, Ozkan M, Inan I, Kurt I, Bilgic H

Therapeutics and Clinical Risk Management 2012, 8:369-372

Published Date: 27 August 2012

The first case of cutaneous infection with Mycobacterium parascrofulaceum

Zong WK, Zhang XD, Wang HS, Xu XL, Wang QL, Tian WW, Jin YL, Wu QX, Tang MY

Therapeutics and Clinical Risk Management 2012, 8:353-358

Published Date: 15 August 2012

Training in peroral endoscopic myotomy (POEM) for esophageal achalasia

Eleftheriadis N, Inoue H, Ikeda H, Onimaru M, Yoshida A, Hosoya T, Maselli R, Kudo S

Therapeutics and Clinical Risk Management 2012, 8:329-342

Published Date: 23 July 2012

Knowledge of adverse drug reaction reporting in first year postgraduate doctors in a medical college

Upadhyaya P, Seth V, Moghe VV, Sharma M, Ahmed M

Therapeutics and Clinical Risk Management 2012, 8:307-312

Published Date: 19 June 2012

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab

Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P

Therapeutics and Clinical Risk Management 2012, 8:295-306

Published Date: 19 June 2012

Difficult airway and difficult intubation in postintubation tracheal stenosis: a case report and literature review

Zarogoulidis P, Kontakiotis T, Tsakiridis K, Karanikas M, Simoglou C, Porpodis K, Mitrakas A, Esebidis A, Konoglou M, Katsikogiannis N, Zervas V, Aggelopoulou C, Mikroulis D, Zarogoulidis K

Therapeutics and Clinical Risk Management 2012, 8:279-286

Published Date: 27 June 2012

Duloxetine in the management of chronic musculoskeletal pain

Smith HS, Smith EJ, Smith BR

Therapeutics and Clinical Risk Management 2012, 8:267-277

Published Date: 19 June 2012

Pharmacological management of binge eating disorder: current and emerging treatment options

McElroy SL, Guerdjikova AI, Mori N, O’Melia AM

Therapeutics and Clinical Risk Management 2012, 8:219-241

Published Date: 8 May 2012

Maximizing neuroprotection: where do we stand?

Kuffler DP

Therapeutics and Clinical Risk Management 2012, 8:185-194

Published Date: 10 April 2012

Interdisciplinary three-step strategy to treat aortic stenosis and coronary artery disease in a patient with end-stage chronic obstructive pulmonary disease

Michel S, Bigdeli AK, Beiras-Fernandez A, Schmitz C, Wolf M, Sodian R, Kaczmarek I

Therapeutics and Clinical Risk Management 2012, 8:181-183

Published Date: 11 April 2012

Measurement complexity of adherence to medication

Galato D, Schuelter-Trevisol F, Piovezan AP

Therapeutics and Clinical Risk Management 2012, 8:169-171

Published Date: 2 April 2012

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis

Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O'Regan C, Mills EJ

Therapeutics and Clinical Risk Management 2012, 8:105-130

Published Date: 9 March 2012

Ruxolitinib for the treatment of myelofibrosis: its clinical potential

Ostojic A, Vrhovac R, Verstovsek S

Therapeutics and Clinical Risk Management 2012, 8:95-103

Published Date: 1 March 2012

NIHSS and acute complications after anterior and posterior circulation strokes

Boone M, Chillon JM, Garcia PY, Canaple S, Lamy C, Godefroy O, Bugnicourt JM

Therapeutics and Clinical Risk Management 2012, 8:87-93

Published Date: 27 February 2012

Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus

Hagihara M, Umemura T, Mori T, Mikamo H

Therapeutics and Clinical Risk Management 2012, 8:79-86

Published Date: 17 February 2012

Coronary artery disease in Africa and the Middle East

Almahmeed W, Arnaout MS, Chettaoui R, Ibrahim M, Kurdi MI, Taher MA, Mancia G

Therapeutics and Clinical Risk Management 2012, 8:65-72

Published Date: 16 February 2012

Metabolic syndrome in a sample of the 6- to 16-year-old overweight or obese pediatric population: a comparison of two definitions

Saffari F, Jalilolghadr S, Esmailzadehha N, Azinfar P

Therapeutics and Clinical Risk Management 2012, 8:55-63

Published Date: 2 February 2012

New treatment options for lupus – a focus on belimumab

Chiche L, Jourde N, Thomas G, Bardin N, Bornet C, Darque A, Mancini J

Therapeutics and Clinical Risk Management 2012, 8:33-43

Published Date: 26 January 2012

Clinical utility of adjunctive retigabine in partial onset seizures in adults

Rejdak K, Luszczki JJ, Błaszczyk B, Chwedorowicz R, Czuczwar SJ

Therapeutics and Clinical Risk Management 2012, 8:7-14

Published Date: 20 January 2012